Nifty Pharma News, Corporate filings and Earnings/Conference Calls

Name: Latest research reports of Lupin Ltd. authored by Geojit BNP Paribas and published by - Trendlyne research reports.
Item: Lupin Ltd.
Rating: 3
Author: Geojit BNP Paribas

Keep track of all breaking news and updates on Nifty Pharma from all sources in a single place.

Load latest

Alkem Laboratories Ltd.

13 Mar 2025

4906.20

1.12%

Company Update

Alkem Laboratories Ltd - 539523 - Announcement under Regulation 30 (LODR)-Press Release / Media Release

BSE India

This is to inform you that US FDA had conducted a Bioresearch Monitoring (BIMO) inspection at the Company''s Bioequivalence Centre located at Taloja, Maharashtra from 10th March, 2025 to 13th March, 2025. Kindly take the same on record.

pdf

Sun Pharmaceutical Industries Ltd.

13 Mar 2025

1750.25

1.03%

Sun Pharma is betting big on speciality. Will it pay off?

livemint

Analysts expect Sun to continue to be more aggressive in chasing speciality assets, but a successful launch is necessary for the stock to gain brownie points.

Sun Pharmaceutical Industries Ltd.'s price crossed above 200Day SMA today

Zydus Lifesciences Ltd.

13 Mar 2025

917.25

0.81%

Company Update

Zydus Lifesciences Ltd - 532321 - Announcement under Regulation 30 (LODR)-Newspaper Publication

BSE India

Newspaper publication of notice of loss of share certificate of the Company

pdf

Lupin Ltd.

13 Mar 2025

2085.70

1.20%

LUPIN LIMITED

Hold: Lupin Ltd.

Target

Geojit BNP Paribas

Lupin Ltd.'s price crossed above 200Day SMA today

Mankind Pharma Ltd.

12 Mar 2025

2244.85

3.85%

Mankind Pharma Launches Generic Version Of Empagliflozin Diabetes Medication

NDTV Profit

The launch follows the expiration of Boehringer Ingelheim's patent for Empagliflozin in India.

Mankind Pharma Ltd. is trading below all available SMAs

Zydus Lifesciences Ltd.

12 Mar 2025

917.25

0.81%

Company Update

Zydus Lifesciences Ltd - 532321 - Announcement under Regulation 30 (LODR)-Press Release / Media Release

BSE India

Zynext Ventures invests in Illexcor Therapeutics to advance novel oral therapy for sickle cell disease.

pdf

Alkem Laboratories Ltd.

12 Mar 2025

4906.20

1.12%

Key diabetes drug price crashes up to 90% as generic versions launched

Business Standard

Mankind, Alkem, Glenmark launch generic versions of empagliflozin

Alkem Laboratories Ltd. has lost -20.05% in the last 6 Months

Dr. Reddy's Laboratories Ltd.

12 Mar 2025

1187.20

1.29%

Company Update

Dr Reddys Laboratories Ltd - 500124 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - …

BSE India

Schedule of Analyst/Institutional meet

pdf

Aurobindo Pharma Ltd.

12 Mar 2025

1174.15

0.89%

Company Update

Aurobindo Pharma Ltd - 524804 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation

BSE India

Intimation of Plant visit by investor group on March 19, 2025

pdf

Glenmark Pharmaceuticals Ltd.

12 Mar 2025

1478.80

-0.53%

Glenmark launches Empagliflozin for diabetes in India under Glempa brand

Business Standard

Glenmark Pharmaceuticals on Wednesday said it has launched a medication for glycemic control and weight-loss for diabetes patients. The Mumbai-based drug firm has launched Empagliflozin, a widely recognised SGLT2 inhibitor, under the brand name Glempa (Empagliflozin 10/25 mg), along with its fixed-dose combinations (FDCs)'?Glempa-L (Empagliflozin 10/25 mg + Linagliptin 5 mg) and Glempa-M (Empagliflozin 12.5 mg + Metformin 500/1000 mg). The medications are designed to improve glycemic control in adults with type 2 diabetes mellitus while also reducing cardiovascular outcomes in patients with cardiovascular risk. Studies have demonstrated several benefits of Empagliflozin, including effectively improving glycemic control, supporting weight-loss, and reducing cardiovascular-renal risks in patients with type 2 diabetes mellitus. Empagliflozin has also demonstrated benefits in heart failure patients by lowering the cardiovascular death or hospitalisation. "The launch of Glempa range ..

Glenmark Pharmaceuti.. has an average target of 1702.25 from 5 brokers.

No results found

Is Nifty Pharma worth buying?

303 Votes:

Buy 79.21%

Sell 11.55%

Hold 9.24%

Nifty Pharma PB	5.2
Nifty Pharma PE	32.3
Nifty Pharma DIV	0.7
Nifty Pharma EPS	655.7